3. 2013 World Symposium on PH CTEPH Diagnosisa

4. 2013 World Symposium on PH (cont) CTEPH Treatmenta

5. Riociguat in Inoperable or Residual CTEPH and PAH

6. Switching Therapy in CTEPH and PAH

7. Switching Therapy in CTEPH and PAH (cont)

8. Case Presentation A PAH Patient With Worsening Symptoms on ERA

9. Initial Improvement With Bosentan Therapy

10. At 2 Years Decreased Exercise Capacity, FC, and Right Ventricular Function

11. Physical Examination

12. Current Prognostic Evaluation

13. RHC Frequency Recommendationsa,b

14. Recommended Treatment Goals

15. Riociguat in PAH PATENT-1 Trial

16. Riociguat Efficacy Secondary End Points

17. Other Combination Therapy Options

18. Switching Therapy Follow-up Recommendations

19. Individualizing Treatment With Riociguat

20. Individualizing Treatment With Riociguat (cont)

21. Case Presentation Riociguat Treatment 3-Month Follow-Up

22. CTEPH and PAH Importance of Proper Diagnosis

23. Abbreviations

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)

28. References (cont)